Japan Asia Investment

JAIC is Japan's largest independent venture capital firm and has accumulated experience and know-how over a period of 15 years as a pioneer of venture capital investments in Asia. Building on such strengths, they are establishing a globally linked organization that pursues investment opportunities centering on the three regions of Japan, Asia, and the United States.

Enen Chiyo

CEO

Hirohiko Miwa

Director

Ping Zhang

Managing Partner

66 past transactions

KIC holdings

Venture Round in 2020
KIC Holdings engages in asset management, securitization, investment, advisory services,and real estate development businesses. They offer detailed services for due diligence, acquisition, financing, management planning, and asset management for medium- to large-size distribution centres, warehouses, and trunk rooms.

Integral Geometry Science

Venture Round in 2019
IGS investigates theories and methods for visualizing object internal structures. The company is developing, manufacturing, and selling the world's highest performance measurement system based on Dr. Kimura's and others' multi-path scattered field theory, which is known as an unsolved problem in the history of applied mathematics.

Croco

Venture Round in 2019
CROCO offers solutions for implementing content marketing, including current situation analysis, policy formulation, planning, production, editing, proofreading, submission, coding, effect measurement, maintenance, and operation.

Last One Mile

Venture Round in 2018
Last One Mile provides the infrastructure to allow connections between telecommunications facility and its customers

YAMAP

Series B in 2018
YAMAP is an internet company that specializes in web and application development for mountain climbing and outdoor activity.

Megakaryon

Series C in 2017
Megakaryon is a medical research company that develops and sells blood products.

Nippon Souken

Venture Round in 2017
Nippon Souken is a financial service agency that specializes in risk management and insurance services.

REGiMMUNE

Venture Round in 2017
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

FacePeer

Venture Round in 2017
FacePeer is a development and operation of Facehub, a video call platform for companies, and Viewhub, a web interview service specializing in job interviews. The company provides optimal solutions according to the operating system and issues. By enhancing operational effectiveness and changing work practices, FacePeer not only supports the long-term expansion of businesses but also fosters a connected society where everyone can grow.

Laxus Technologies

Series B in 2017
Laxus Technologies is an online fashion-sharing platform that allows users to borrow designer handbags. They manage the application for unrestricted brand bag subscriptions. They allow consumers to directly buy goods or services from a seller over the internet using a web browser or a mobile app. .

J-ARM

Venture Round in 2016
J-ARM is a medical laboratory that facilitates the implementation of cell therapy and regenerative medicine.

Wonderplanet

Venture Round in 2016
Wonderplanet designs and develops native language applications and games for smart phones and tablets. The company was founded in 2012 and is based in Nagoya, Japan.

Ligua

Venture Round in 2016
Ligua is an organization that provides problem-solving consulting services to the healthcare sector. The company assists financial, health-related, and wellness-related businesses. Ligua wants to provide a healthy life where everyone can experience genuine enrichment and happiness.

TORICO

Venture Round in 2016
TORICO Operates an online platform and application, which sells books, e-books, and more. The company was founded in 2005 and is based in Chisoda, Timis.

Wonderleague

Venture Round in 2016
Wonderleague is a manufacturer of VR and AR goggles and controllers intended to provide the best quality products and experiences.The company leverages technology to build AR and VR headsets and controllers available on ios and android devices and also develop an AR platform, enabling customers to have an interactive experience.

FacePeer

Venture Round in 2016
FacePeer is a development and operation of Facehub, a video call platform for companies, and Viewhub, a web interview service specializing in job interviews. The company provides optimal solutions according to the operating system and issues. By enhancing operational effectiveness and changing work practices, FacePeer not only supports the long-term expansion of businesses but also fosters a connected society where everyone can grow.

FunPep

Venture Round in 2015
FunPep engages in the research and development of pharmaceuticals, cosmetics, and medical devices based on functional peptides. They produces intractable ulcer treatment drugs, antibody drugs, pharmaceutical drugs, and other products. The goal of FunPep is to replace antibody medicines with next-generation pharmaceutical products, specifically antibody-inducing peptide.

Aoi.co

Series B in 2015
Aoi.Co has acquired over 3,000 students as users to date and unveiled that the entrance exam passing rate of users for their preferred universities has reached 86.3%. The firm plans to use the funds to strengthen its system development capability and introduce a learning state monitoring app for parents in September.

Eltes

Venture Round in 2015
Eltes specializes in providing solutions by big data analysis specialized in risk detection.

FunPep

Venture Round in 2015
FunPep engages in the research and development of pharmaceuticals, cosmetics, and medical devices based on functional peptides. They produces intractable ulcer treatment drugs, antibody drugs, pharmaceutical drugs, and other products. The goal of FunPep is to replace antibody medicines with next-generation pharmaceutical products, specifically antibody-inducing peptide.

TMS

Convertible Note in 2015
TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.

Megakaryon

Series B in 2015
Megakaryon is a medical research company that develops and sells blood products.

REGiMMUNE

Series D in 2014
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

JMC

Venture Round in 2012
JMC manufactures and sells prototypes, parts, and products using 3D printers, sand casting for industrial CT, and inspection and measurement services. They also provide 3D printer output, a CT biology encyclopedia, and 3DiH printer services.

REGiMMUNE

Series C in 2012
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

TMS Japan

Seed Round in 2011
TMS is a research company on medical products, medical products, medical products, medical equipment and medical consumables.

Richmedia

Seed Round in 2011
Rich Media offers media portal, web creation, and search engine optimization services.

BioAmber

Series A in 2010
BioAmber is a private US company registered in the state of Delaware. The company, formerly known as DNP Green Technology, changed its name to BioAmber following its acquisition of its joint venture with ARD. Following the transaction, they adopted the name BioAmber, which had been used to that point by the joint venture.

Zibolan

Series A in 2009
Zibolan is a digital marketing company provides internet marketing and search engine optimisation.

Analogix Semiconductor

Series B in 2009
Analogix Semiconductor designs and manufactures high-performance analog and mixed-signal semiconductors for the Digital Media market. Analogix is a leader in providing semiconductor solutions for DisplayPort, the next-generation digital interconnect for the Personal Computer. Analogix also provides a full suite of HDMI 1.3 and 1.2 transmitter and receiver solutions for the distribution of high-definition video and audio in consumer electronics. Analogix is based in Santa Clara, Calif., with offices in Beijing, China, Taipei, Taiwan and Tokyo, Japan.

Chiral Quest

Series B in 2009
Chiral Quest chemists have many years of process development experience. They rapidly take a ‘lab-scale' process and develop a practical, scalable process for cost- effective manufacturing.

Palo Alto Networks

Series C in 2008
Palo Alto Networks is a cybersecurity company that offers cybersecurity solutions for organizations.

SALES ROBOTICS

Seed Round in 2008
SALES ROBOTICS is a provider of an a service platform designed to provide business support services of digital content specialized for foreign language education.The company's service provides language lessons and provides a marketing and sales platform which offers system development and information technology services, enabling businesses to analyze data and prepare sales strategy.

REGiMMUNE

Series B in 2008
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

Chestnut Medical

Series C in 2008
Chestnut Medical Technologies, Inc. was founded to pioneer new minimally invasive therapies for Interventional Neuroradiology. Chestnut's mission is to develop technologies that are easier to use while improving outcomes and reducing complications in the treatment of neurovascular disease.

REGiMMUNE

Series B in 2008
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

Ecrio

Series C in 2007
Ecrio provides optimized, standards compliant software clients and development resources to mobile phone service providers and device manufacturers for mobile commerce and real time communications. The Ecrio Mobile Communications Client Suite (MCCS) transforms everyday applications into communication-rich applications. The MCCS framework reduces the complexity and effort required to add rich communication functions to applications ranging from Voice and SMS to video telephony, content sharing, social communications and enterprise solutions. Applications running in common application environments, developed using standard SDK tools on a wide range of device types and platforms can be easily upgraded to communication-rich applications using the framework’s rich set of functions and its simple access methods. The Ecrio MCCS solves the challenges of enabling and sharing high-value and complex communication capabilities among multiple applications and devices, reducing the incremental effort, cost, and risk of deploying and using new LTE and IMS service capabilities. It accelerates application development resulting in more uses and optimized experiences expanding the individual value and market reach and achieving a higher value for the service capability investment.

Moshimo

Venture Round in 2007
Moshimo enables small businesses to easily sell merchandise online by offering an efficient way to build an online shop front. In addition, Moshimo provides drop shipping, a supply chain management technique where the wholesale supplier, not the small business, holds and ships the product. This system eliminates the difficulties of designing an online store, holding inventory, and sending goods. Moshimo offers their users the opportunity to sell over 350,000 different products sourced from more than 800 wholesale suppliers.

Game Studio

Venture Round in 2007
A privately held technology company headquartered in London.

Tudou

Series B in 2007
Tudou is a Chinese video sharing website that enables young users to get their voices heard on mainstream network media platforms. Launched on April 15, 2005, by its founder Wang Tei, Tudou was listed on NASDAQ on August 17 that same year. Tudou.com completed its fifth round of financing for $40 million dollars in 2010. In 2012, Tudou was acquired by Youku in a stock-for-stock transaction, and the merger of China's two biggest online video companies was finalized after shareholders approved the deal on August 20, 2012. The new entity was named Youku Tudou, Inc. According to iResearch, the number of monthly unique visitors to the site increased from approximately 182 million in December 2010 to about 227 million in May 2013, giving Youku Tudou, Inc. the advantage in terms of user base over its major rivals, Sohu, PPTV and iQiyi.

All Ads

Venture Round in 2007
All Ads offers LTV digital marketing services for business professionals to help optimize advertising cost-effectiveness. The company champions LTV marketing, leveraging the synergy of data, technology, and consulting within the broader spectrum of digital marketing. Its goal is to contribute to the growth of advertisers' businesses.

B.Creation

Venture Round in 2007
B.Creation offers digital services and development of smartphone application useful for fishing and outdoors. The company was established on March 29, 2004.

REGiMMUNE

Series A in 2007
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

BlogBus

Series A in 2006
BlogBus.com is the first Blog hosting service providers (Blog Service Provider), is also the first commercial operation of the paid services provided by Chinese Blog Site, Blog in Chinese industry reputation.

Broncus Medical

Series F in 2006
Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

REGiMMUNE

Seed Round in 2006
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

Tixa Internet Technology

Series B in 2006
Tixa Internet Technology headquartered in Beijing and formerly known as VeryE, is a China leader in providing web-empowered products, systems, and services. In March 2004, after securing financing from Mitsui Sumitomo Financial Group, VeryE was reconstructed into Tixa Internet Technology Co., Ltd.

Azteq Mobile

Venture Round in 2006
Azteq Mobile manufactures and markets mobile devices, palm tops, communication equipment, and handheld devices. The company is based in Walnut Creek, California.

SymBio Pharmaceuticals

Series B in 2006
SymBio Pharmaceuticals Limited operates as a biopharmaceutical company. It offers Symbenda medicine for treating low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia in Singapore. The company was founded in 2005 and is headquartered in Tokyo, Japan.

Crooz

Venture Round in 2006
Crooz, a company based in Japan that offers smartphone games to the Japanese and global markets. CROOZ, Inc. is one of the leading mobile social game providers in Japan. We also publish original titles on “Mobage” and other leading social gaming platforms. Some of our games are grossing over US$1MM per month. We are currently expanding the business internationally to capitalize on the rapid growth of global smartphone game industry., and in doing so, we aim to become a dominant player in both domestic and global markets.

InPhase Technologies

Series C in 2005
InPhase Technologies is a storage company focused on holographic data storage technology.

SMS

Venture Round in 2005
SMS is mainly engaged in the information operation businesses in nursing care, healthcare, career, senior life and overseas fields to business operators and end user, among others.
Magink is a privately held company founded in 2000 with offices in the U.K and Israel. magink addresses the Out-of-Home media market; outdoor advertising, retail signage, public information, transportation, in-store point-of-purchase, promotional displays and entertainment. Magink's new product lines (indoor and outdoor solutions) are currently being tested and deployed in several cities globally. magink is committed to the continuous development of its core technology: full-color, commercially-viable digital ink display systems. This proprietary technology provides high resolution, high contrast, full-color, low energy consumption and cost effective digital display applications to a broad array of global industries.

Beat Holdings Limited

Venture Round in 2003
Beat Holdings Limited(Formerly known as Xinhua Finance Limited) is a multi-disciplinary group company doing businesses in China and the rest of Asia, including Japan. The company currently offers products and devices in the areas of financial services, public relations and developing and operating application software for smartphones, telecom software platforms, global messaging gateways and mobile advertising platforms. The Company offers products and services in the areas of financial services. Listed on TSE's Second Section (9399), Xinhua Holdings is headquartered in Hong Kong, with a global network spanning China and Japan. China's economic development has drastically improved the country's standard of living considerably and has set the stage for China to focus on sectors that are vital for future sustainable development. Combining their financial expertise in China and global network, they seek to introduce internationally-proven standards and essential products and services that facilitate business and investment in China. At Xinhua Holdings, they provide the tools and know-how upon which global and domestic organizations can execute high-value decisions with confidence, care, and clarity. Leveraging the value of their products and services, client base and brand names, they, aim to serve as a bridge between China's markets, business opportunities and the world and act as a business incubator in China.

Istyle

Series B in 2003
istyle, Inc. engages in the management of beauty-related online platforms as well as the provision of advertising, marketing, and research services. It operates through the following segments: On Platform, Beauty Service, Global, and Others. The On Platform segment deals with domestic and overseas marketing, as well as premium membership services. The Beauty Service segment manages domestic cosmetics electronic commerce sites in addition to its specialty shop @cosme store. The Global segment includes services developed overseas. The Others segment covers beauty staff dispatching and investment training services. It has overseas subsidiaries including in Taiwan, China, Hong Kong, Malaysia, Singapore, Thailand, and The United States.

Rinat Neuroscience

Series B in 2003
Rinat, which means "happiness" in Hebrew, was formed in 2001 when Genentech, a leader in the development of therapeutic antibodies, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing antibody drugs for the treatment of diseases and disorders of the nervous system.

Triage Medical

Series B in 2003
Triage Medical Inc., an Irvine, Calif.-based developer orthopedic trauma devices.

Sosei Group

Series B in 2003
Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing their platform technologies - GPCR structure-based drug design platform technology, peptide platform technologies and nanotechnology - they have established a product pipeline with first/best in class potential. Through development and commercialization partnerships they have already delivered three medicines to the market (two COPD bronchodilators and an emergency contraceptive), which generate significant and stable revenue streams that enable further growth.

InPhase Technologies

Series B in 2002
InPhase Technologies is a storage company focused on holographic data storage technology.

Calmetrics

Series C in 2001
Calmetrics manufactures reference standards for calibrating virtually any XRF coating thickness and composition analysis system. The company offers a wide range of standards, including thin and thick films, alloy films, bulk standards including precious metals, and other standards for a range of industrial and scientific applications.

Beenos Partners

Venture Round in 2000
Beenos is a platform for startups. Our in-house team of entrepreneurs-in-residence and specialists help you get your ideas off the ground. We’re (the) experts in engineering, design, data science, and business management. We know how to launch a company in this ever changing IT industry, and we’d like to help establish and expand your present and future business. The company was founded in 1999 as NetPrice.com, a provider of eCommerce services. NetPrice.com established Beenos as an incubation program before [pivoting to venture capital in 2014](https://www.techinasia.com/beenos-new-japan-incubator-accelerator-venture-capital-program-hiro-maeda).

Magically

Venture Round in 2000
Magically, Inc., the Worldwide leader in Communication & Collaboration technologies focuses on Personal communication and collaboration components. Magically's technology solutions, designed for the mobile work force and virtual communities, are universally accessible through multiple platforms, in any language and from any Internet enabled device. MagicalDesk, the flagship product, is an award-winning suite of information management tools for the corporate / SME user. Magically's newest product, Magical WorkSpace, is an enterprise application focused on workflow and team collaboration. Based in Redwood City, California, Magically is a privately owned and operated company with offices in Hong Kong, UK and Tokyo.

Silicon Wave

Series C in 2000
Silicon Wave, a San Diego pioneer in the Bluetooth wireless technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.